Novo Nordisk's Wegovy® Gains Preferred Status with CVS Caremark
Novo Nordisk has made significant strides in the obesity treatment landscape by securing Wegovy® as the preferred GLP-1 medication for weight management on CVS Caremark's principal formularies, the largest Pharmacy Benefit Manager in the country. This decision will take effect soon, marking a pivotal moment for patients seeking effective obesity treatments.
Advantages of Wegovy® for Patients
Wegovy® (semaglutide) is an injectable prescription medication designed to assist individuals in their weight loss journey when complemented with a healthy diet and increased physical activity. It is tailored for adults suffering from obesity, as well as those with weight-related health issues. This breakthrough drug is not just limited to weight reduction; it also reduces the risk of major cardiovascular events, such as strokes and heart attacks, specifically in adults with a history of heart disease.
Driving Access and Affordability
In a statement reflecting Novo Nordisk's commitment to enhancing patient experience, Dave Moore, Executive Vice President of US Operations at Novo Nordisk, expressed that the company is devoted to ensuring that Wegovy® is accessible and affordable to those in need. As part of its strategy, Novo Nordisk plans to collaborate with CVS Caremark to further enhance patient access to this innovative treatment.
The FDA has confirmed the availability of all Wegovy® doses, thus solidifying its status as the only approved semaglutide treatment for weight loss. To make it easier for patients, Novo Nordisk launched NovoCare®, providing convenient home shipments of Wegovy® at an affordable price.
Wegovy®: A Revolutionary Treatment
Since its first approval in 2021, Wegovy® has changed how healthcare professionals approach obesity management. It is recognized as the first weekly GLP-1 option equipped to aid in chronic weight management. In 2024, the FDA further expanded its label to cover the reduction of major cardiovascular event risks for adults with known heart conditions and obesity.
Comprehensive Patient Support
Novo Nordisk's support for patients includes a recent update to the Wegovy® savings program, allowing eligible patients to access the $499 per month pricing at local pharmacies, alongside direct shipment options. The purpose of these initiatives is not only to provide treatment but to ensure that patients receive adequate support throughout their therapy.
Wegovy®: Safety and Side Effects
While Wegovy® can significantly aid in weight loss and health improvement, it is essential for patients to be aware of its possible side effects. Serious side effects may include pancreatitis, thyroid tumors, gallbladder issues, kidney problems, and low blood sugar levels if taken with other diabetes medications. Therefore, it is crucial to maintain open communication with healthcare providers throughout the treatment process.
About Novo Nordisk
Novo Nordisk has established itself as a leader in diabetes and chronic disease care for over a century. Anchored by innovation, the company aims to provide comprehensive solutions for managing serious health conditions, including obesity and endocrine disorders. With a reputation for maintaining high ethical standards, Novo Nordisk emphasizes responsible business practices while enhancing healthcare access.
Commitment to Patient Well-Being
With a presence in the US spanning four decades, Novo Nordisk employs over 10,000 individuals across various states. The company is dedicated to ensuring that its innovative medicines are both effective and accessible, reaffirming its commitment to improving patient lives.
Frequently Asked Questions
What is Wegovy® used for?
Wegovy® is primarily used to assist in weight loss for adults who are obese, and it may also help reduce the risk of cardiovascular events for those with heart conditions.
How does Wegovy® work?
Wegovy® works by mimicking the GLP-1 hormone, which regulates appetite and food intake, thus supporting weight loss when combined with a healthy diet and exercise.
What are the side effects of Wegovy®?
Some common side effects of Wegovy® include nausea, vomiting, diarrhea, headaches, and fatigue. Serious side effects may involve pancreas inflammation or thyroid tumors.
Is Wegovy® suitable for children?
Wegovy® is not approved for use in children under 12 years of age, and its safety in that age group is not established.
How can patients access Wegovy®?
Patients can access Wegovy® through their healthcare providers, and Novo Nordisk offers various assistance programs to help facilitate affordability and access.
